Novel immunological targets in rheumatic diseases: clues from current therapies

Fulvio D'Acquisto; Lorenza Rattazzi; Giuseppa Piras; Maria Letteria Galuppo

doi:10.1016/j.drudis.2014.06.021

Novel immunological targets in rheumatic diseases: clues from current therapies

Fulvio D'Acquisto, Lorenza Rattazzi, Giuseppa Piras, Maria Letteria Galuppo

Research output: Contribution to journal › Review article › peer-review

Abstract

Many years have elapsed since the discovery of immunomodulators as effective therapeutics for the treatment of rheumatic diseases, and we are still learning about their various mechanisms of action. Here, we provide a concise overview of the most recent discoveries in this field of research, focusing in particular on signaling pathways targeted by therapeutics currently used in the clinic. We highlight areas of investigation that could potentially be explored for the development of new classes of antirheumatic drugs.

Original language	English
Pages (from-to)	1155-60
Number of pages	6
Journal	Drug discovery today
Volume	19
Issue number	8
DOIs	https://doi.org/10.1016/j.drudis.2014.06.021
Publication status	Published - Aug 2014

Keywords

Animals
Antirheumatic Agents
Humans
Immunologic Factors
Rheumatic Diseases
Signal Transduction
Journal Article
Review

Access to Document

10.1016/j.drudis.2014.06.021

Cite this

@article{ddb7fa13b1b04f1393da9f93aae47cc6,

title = "Novel immunological targets in rheumatic diseases: clues from current therapies",

abstract = "Many years have elapsed since the discovery of immunomodulators as effective therapeutics for the treatment of rheumatic diseases, and we are still learning about their various mechanisms of action. Here, we provide a concise overview of the most recent discoveries in this field of research, focusing in particular on signaling pathways targeted by therapeutics currently used in the clinic. We highlight areas of investigation that could potentially be explored for the development of new classes of antirheumatic drugs.",

keywords = "Animals, Antirheumatic Agents, Humans, Immunologic Factors, Rheumatic Diseases, Signal Transduction, Journal Article, Review",

author = "Fulvio D'Acquisto and Lorenza Rattazzi and Giuseppa Piras and Galuppo, {Maria Letteria}",

year = "2014",

month = aug,

doi = "10.1016/j.drudis.2014.06.021",

language = "English",

volume = "19",

pages = "1155--60",

journal = "Drug discovery today",

issn = "1359-6446",

publisher = "Elsevier",

number = "8",

}

TY - JOUR

T1 - Novel immunological targets in rheumatic diseases

T2 - clues from current therapies

AU - D'Acquisto, Fulvio

AU - Rattazzi, Lorenza

AU - Piras, Giuseppa

AU - Galuppo, Maria Letteria

PY - 2014/8

Y1 - 2014/8

N2 - Many years have elapsed since the discovery of immunomodulators as effective therapeutics for the treatment of rheumatic diseases, and we are still learning about their various mechanisms of action. Here, we provide a concise overview of the most recent discoveries in this field of research, focusing in particular on signaling pathways targeted by therapeutics currently used in the clinic. We highlight areas of investigation that could potentially be explored for the development of new classes of antirheumatic drugs.

AB - Many years have elapsed since the discovery of immunomodulators as effective therapeutics for the treatment of rheumatic diseases, and we are still learning about their various mechanisms of action. Here, we provide a concise overview of the most recent discoveries in this field of research, focusing in particular on signaling pathways targeted by therapeutics currently used in the clinic. We highlight areas of investigation that could potentially be explored for the development of new classes of antirheumatic drugs.

KW - Animals

KW - Antirheumatic Agents

KW - Humans

KW - Immunologic Factors

KW - Rheumatic Diseases

KW - Signal Transduction

KW - Journal Article

KW - Review

U2 - 10.1016/j.drudis.2014.06.021

DO - 10.1016/j.drudis.2014.06.021

M3 - Review article

C2 - 24984284

SN - 1359-6446

VL - 19

SP - 1155

EP - 1160

JO - Drug discovery today

JF - Drug discovery today

IS - 8

ER -